---
title: "Worldwide Clinical Trials to acquire Catalyst"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273358133.md"
description: "Worldwide Clinical Trials has agreed to acquire Catalyst Clinical Research, an oncology CRO, to enhance its capabilities in oncology and expand its global reach. The integration will combine Catalyst’s solutions with Worldwide’s portfolio, improving service offerings and operational efficiency. Catalyst's chairman will join Worldwide's board, and its CEO will be part of Worldwide's leadership team. The acquisition is pending regulatory approvals and is expected to conclude in Q1 2026."
datetime: "2026-01-22T10:21:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273358133.md)
  - [en](https://longbridge.com/en/news/273358133.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273358133.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/273358133.md) | [English](https://longbridge.com/en/news/273358133.md)


# Worldwide Clinical Trials to acquire Catalyst

The deal includes adopting complementary technology platforms and practices to enhance efficiency and visibility across development. Credit: PeopleImages / Shutterstock.com.

Worldwide Clinical Trials has entered a definitive agreement to acquire oncology contract research organisation (CRO) Catalyst Clinical Research.

The transaction will see Catalyst Board chairman Nick Dyer join Worldwide’s board of directors while Catalyst president and CEO Nik Morton will become part of Worldwide’s executive leadership team.

This acquisition aims to establish Worldwide as an oncology-focused CRO while maintaining depth in several therapeutic areas and expanding its global reach for clinical trials.

Free Sample

### Download sample pages of selected reports

Explore a selection of report samples we have handpicked for you. Get a preview of the insights inside. Download your free copy today.

The integration will combine Catalyst’s solutions, Catalyst Flex and Catalyst Oncology, with Worldwide’s existing portfolio, offering customers expanded services for full-service, functional service provider (FSP) resourcing, and hybrid models.

Additionally, the deal includes the adoption of complementary technology platforms and operational practices to enhance data efficiency and visibility across the development lifecycle.

Worldwide will acquire Catalyst for an undisclosed sum pending customary closing conditions and regulatory approvals. The transaction is expected to conclude in Q1 2026.

Worldwide is backed by Kohlberg while Catalyst is a portfolio company of QHP Capital. BofA Securities advised Catalyst exclusively; Smith Anderson was its legal counsel. Greenberg Traurig acted as legal counsel for Worldwide.

Worldwide CEO Alistair Macdonald said: “Bringing Worldwide and Catalyst together elevates our capabilities in oncology and provides a new solution for our collective customers.

“We are excited to add Catalyst’s deep operational expertise and oncology credibility to our own well-known CNS specialist CRO capabilities to create a differentiated biotech-oriented oncology solution. Our combined customers seek focused senior executive connection and attention, predictability, speed, flexibility, and scientific rigour.

“They will benefit from the addition of a scalable FSP model with integrated onshore/offshore service lines while we leverage advanced business management tools and AI to drive operational excellence.”

In May 2024, Medidata announced an expanded partnership with Worldwide to expedite clinical trials and enhance the patient experience.

### Unlock up to 35% savings on GlobalData reports

Use the code at checkout in the report store

-   ### 20% OFF
    
    Buy 2 reports
    
    Use code:
    
    #### Bundle20
    
-   ### 25% OFF
    
    Buy 3 reports
    
    Use code:
    
    #### Bundle25
    
-   ### 30% OFF
    
    Buy 4 reports
    
    Use code:
    
    #### Bundle30
    
-   ### 35% OFF
    
    Buy 5+ reports
    
    Use code:
    
    #### Bundle35
    

Valid on all reports priced $995 and above. Cannot be combined with other offers.

#### Still deciding what will work best for your business?

Ask our experts for help.

Enquire before buying

## 相關資訊與研究

- [ZAWYA-PRESSR: Burjeel Medical City launches Neuro-Oncology Center](https://longbridge.com/zh-HK/news/281003303.md)
- [YES Bank names S Anantharaman as CRO to strengthen risk management](https://longbridge.com/zh-HK/news/281393377.md)
- [Fda issuance of a priority review voucher to the sponsor of a rare pediatric disease product application- federal register website](https://longbridge.com/zh-HK/news/281378968.md)
- [Symeres and Ambagon collaborate for colorectal cancer molecules](https://longbridge.com/zh-HK/news/281331025.md)
- [EXCLUSIVE: AI Turns 'Bad Leavers' Into Bigger Security Threats, RFA CRO Says](https://longbridge.com/zh-HK/news/281077456.md)